- November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
- August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
- July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
- May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
- March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD
More posters
|
November 11, 2011 S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
Joan P Blonder, Sarah C Mutka, Xicheng Sun, Daniel W Drolet, Dorothy Colagiovanni, Gregory D Lyng, Charles Scoggin, Gary J Rosenthal
S-nitrosoglutathione reductase (GSNOR) is a Class III alcohol dehydrogenase (ADH) that represents a novel therapeutic target in inflammatory bowel disease (IBD). GSNOR may contribute to IBD through dysregulated activity and thus altered metabolism of its substrate, S-nitrosoglutathione (GSNO), an abundant low molecular weight S-nitrosothiol (SNO).
GSNO serves as a reservoir for nitric oxide (NO), exerts potent anti-inflammatory actions, and maintains epithelial barrier functions in the gut. These studies determined the efficacy of small molecule inhibitors of GSNOR (N6022 and N6547; Table 1) in mouse models of dextran sulfate sodium (DSS) colitis. More…poster PDF(787Kb)
Comments are closed.
|
- January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
- December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
- February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
- January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
- August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
- July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
- April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement
|
